Ipsen
ISIN: FR0010259150 | Ticker: IPN | LEI: 549300M6SGDPB4Z94P11
Country: France
Improving lives and health outcomes.
Ipsen’s vision is to be a leading global mid-size biopharmaceutical company, with a focus on transformative medicines in three key therapeutic areas: oncology, rare disease and neuroscience.
At Ipsen, we’re dedicated to improving people’s lives and health outcomes. Our 5,700 employees around the world are committed to tackling areas of high unmet medical need to improve the quality of life of patients and caregivers.
1929
Served areaWorldwide
Headcount5,700
Headquarters65 Quai Georges Gorse, 92100 Boulogne-Billancourt – France
| Line item in (eur) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Assets | N/A | 4,313,000,000.00 | 4,990,500,000.00 | 5,607,900,000.00 |
| Noncurrent Assets | N/A | 2,734,200,000.00 | 3,036,700,000.00 | 3,210,300,000.00 |
| Property Plant And Equipment | N/A | 646,600,000.00 | 647,500,000.00 | 581,400,000.00 |
| Goodwill | N/A | 592,800,000.00 | 623,200,000.00 | 579,900,000.00 |
| Intangible Assets Other Than Goodwill | N/A | 1,121,100,000.00 | 1,370,000,000.00 | 1,585,400,000.00 |
| Investment Accounted For Using Equity Method | N/A | 19,100,000.00 | 26,200,000.00 | 26,400,000.00 |
| Deferred Tax Assets | N/A | 243,200,000.00 | 258,700,000.00 | 321,100,000.00 |
| Other Noncurrent Financial Assets | N/A | 23,100,000.00 | 100,000.00 | 100,000.00 |
| Noncurrent Investments Other Than Investments Accounted For Using Equity Method | N/A | 84,500,000.00 | 106,900,000.00 | 109,800,000.00 |
| Other Noncurrent Assets | N/A | 3,800,000.00 | 4,300,000.00 | 6,100,000.00 |
| Current Assets | N/A | 1,578,800,000.00 | 1,953,800,000.00 | 2,397,600,000.00 |
| Inventories | N/A | 213,900,000.00 | 219,400,000.00 | 284,100,000.00 |
| Current Trade Receivables | N/A | 476,200,000.00 | 564,300,000.00 | 632,500,000.00 |
| Current Tax Assets Current | N/A | 83,600,000.00 | 122,800,000.00 | 41,200,000.00 |
| Other Current Financial Assets | N/A | 48,900,000.00 | 11,700,000.00 | 31,000,000.00 |
| Cash and cash equivalents | N/A | 642,500,000.00 | 814,700,000.00 | 1,169,300,000.00 |
| Other Current Assets | N/A | 113,700,000.00 | 221,000,000.00 | 239,500,000.00 |
| Equity And Liabilities | N/A | 4,313,000,000.00 | 4,990,500,000.00 | 5,607,900,000.00 |
| Equity | 1,765,200,000.00 | 2,117,600,000.00 | 2,737,700,000.00 | 3,336,700,000.00 |
| Issued Capital | N/A | 83,800,000.00 | 83,800,000.00 | 83,800,000.00 |
| Retained Earnings Profit Loss For Reporting Period | N/A | N/A | 646,600,000.00 | 648,600,000.00 |
| Equity Attributable To Owners Of Parent | N/A | 2,131,200,000.00 | 2,735,200,000.00 | 3,337,300,000.00 |
| Noncontrolling Interests | N/A | 2,700,000.00 | 2,500,000.00 | -600,000.00 |
| Noncurrent Liabilities | N/A | 966,000,000.00 | 1,024,400,000.00 | 935,700,000.00 |
| Noncurrent Provisions For Employee Benefits | N/A | 47,400,000.00 | 40,700,000.00 | 18,700,000.00 |
| Other Longterm Provisions | N/A | 32,000,000.00 | 64,000,000.00 | 68,500,000.00 |
| Deferred Tax Liabilities | N/A | 79,900,000.00 | 101,800,000.00 | 77,900,000.00 |
| Other Noncurrent Nonfinancial Liabilities | N/A | 45,100,000.00 | 45,800,000.00 | N/A |
| Other Noncurrent Liabilities | N/A | N/A | 155,100,000.00 | 103,700,000.00 |
| Current Liabilities | N/A | 1,213,100,000.00 | 1,228,400,000.00 | 1,335,400,000.00 |
| Current Provisions | N/A | 45,700,000.00 | 41,600,000.00 | 55,600,000.00 |
| Trade And Other Current Payables To Trade Suppliers | N/A | 495,200,000.00 | 594,700,000.00 | 647,100,000.00 |
| Current Tax Liabilities Current | N/A | 10,800,000.00 | 10,000,000.00 | 11,800,000.00 |
| Other Current Financial Liabilities | N/A | 408,600,000.00 | 129,700,000.00 | 113,800,000.00 |
| Other Current Liabilities | N/A | 250,000,000.00 | 446,800,000.00 | 503,300,000.00 |
| Line item in (eur) | 01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|
| Revenue | 2,686,200,000.00 | 2,999,100,000.00 | N/A |
| Revenue From Sale Of Goods | 2,591,600,000.00 | 2,643,300,000.00 | 3,025,000,000.00 |
| Interest Income On Cash And Cash Equivalents | 2,300,000.00 | 2,400,000.00 | N/A |
| Other Revenue | 94,500,000.00 | 105,400,000.00 | 131,500,000.00 |
| Revenue From Contracts With Customers | N/A | 2,748,600,000.00 | 3,156,400,000.00 |
| Impairment Loss Reversal Of Impairment Loss Recognised In Profit Or Loss | 153,900,000.00 | 9,100,000.00 | 114,300,000.00 |
| Impairment Loss Reversal Of Impairment Loss Recognised In Profit Or Loss | 153,900,000.00 | 9,100,000.00 | 114,300,000.00 |
| Profit Loss From Operating Activities | 524,800,000.00 | 824,700,000.00 | 729,900,000.00 |
| Share Of Profit Loss Of Associates And Joint Ventures Accounted For Using Equity Method | -1,500,000.00 | 400,000.00 | -1,500,000.00 |
| Income Tax Expense Continuing Operations | -17,800,000.00 | 158,300,000.00 | 112,300,000.00 |
| Profit Loss From Continuing Operations | 548,900,000.00 | 631,200,000.00 | 592,100,000.00 |
| Profit Loss From Discontinued Operations | 0.00 | 15,500,000.00 | 55,400,000.00 |
| Profit (loss) | 548,900,000.00 | 646,700,000.00 | 647,500,000.00 |
| Profit Loss Attributable To Owners Of Parent | 548,000,000.00 | 646,600,000.00 | 648,600,000.00 |
| Profit Loss Attributable To Noncontrolling Interests | 900,000.00 | 100,000.00 | -1,100,000.00 |
| Line item in (eur) | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|
| Profit (loss) | 548,900,000.00 | 646,700,000.00 | 647,500,000.00 |
| Adjustments For Income Tax Expense | -66,900,000.00 | 158,300,000.00 | 111,800,000.00 |
| Adjustments For Decrease Increase In Inventories | -7,100,000.00 | -4,400,000.00 | -19,900,000.00 |
| Adjustments For Increase Decrease In Trade Account Payable | 4,500,000.00 | 80,900,000.00 | 29,100,000.00 |
| Adjustments For Impairment Loss Reversal Of Impairment Loss Recognised In Profit Or Loss | 153,900,000.00 | 9,100,000.00 | N/A |
| Adjustments For Unrealised Foreign Exchange Losses Gains | 4,600,000.00 | 2,300,000.00 | -9,500,000.00 |
| Adjustments For Sharebased Payments | 22,500,000.00 | 26,900,000.00 | 26,500,000.00 |
| Other Adjustments For Noncash Items | -36,300,000.00 | -3,600,000.00 | 67,300,000.00 |
| Adjustments For Losses Gains On Disposal Of Noncurrent Assets | -5,700,000.00 | 5,300,000.00 | -7,500,000.00 |
| Income Taxes Paid Refund Classified As Operating Activities | N/A | 181,100,000.00 | 130,700,000.00 |
| Cash Flows From Used In Operating Activities | 771,300,000.00 | 893,300,000.00 | 971,400,000.00 |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | 81,400,000.00 | 96,000,000.00 | N/A |
| Purchase Of Intangible Assets Classified As Investing Activities | 59,300,000.00 | 331,700,000.00 | N/A |
| Other Inflows Outflows Of Cash Classified As Investing Activities | 0.00 | -2,800,000.00 | 13,200,000.00 |
| Cash Flows From Used In Investing Activities | -163,700,000.00 | -332,000,000.00 | -458,600,000.00 |
| Proceeds From Issuing Shares | 0.00 | 0.00 | 0.00 |
| Interest Paid Classified As Financing Activities | N/A | 21,500,000.00 | 18,200,000.00 |
| Cash Flows From Used In Financing Activities | -307,500,000.00 | -421,800,000.00 | -164,200,000.00 |
| Increase (decrease) in cash and cash equivalents before effect of exchange rate changes | 300,100,000.00 | 139,500,000.00 | 348,600,000.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | 500,000.00 | 5,800,000.00 | 5,900,000.00 |
| Cash and cash equivalents | 642,500,000.00 | 814,700,000.00 | 1,169,300,000.00 |
Please note that some sums might not add up.
| Date | Trading entity / Person | Association | Trade type | Volume |
|---|---|---|---|---|
| 27.02.24 | None | Other | Buy | EUR 51,916.20 |
| 31.07.23 | None | Other | Buy | EUR 0.00 |
FR0010259150
LEI549300M6SGDPB4Z94P11
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.